A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy

NCT07408648 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

244

Enrollment

OTHER

Sponsor class

Conditions

Chemotherapy Induced Thrombocytopenia

Interventions

DRUG: hetrombopag 7.5 mg orally once daily

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University